Anti-TNF biologics have proven to be effective in the treatment of RA; however, we speculated that the heterogeneity of RA patients causes many patients’ poor responses to the biologic treatments [30], additionally, the treatment is barely accessible to some patients [31], or they are excluded by a pre-existing malignancy. The gene discussed is TNF; the disease is rheumatoid arthritis.